These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38163624)

  • 1. Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.
    Chou S; Watanabe J
    Antiviral Res; 2024 Feb; 222():105792. PubMed ID: 38163624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
    Chou S; Wu J; Song K; Bo T
    Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
    Chou S; Song K; Wu J; Bo T; Crumpacker C
    J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
    Chou S; Ercolani RJ; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.
    Chou S; Ercolani RJ; Vanarsdall AL
    J Clin Microbiol; 2017 Jul; 55(7):2098-2104. PubMed ID: 28446569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.
    Chou S
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2371-8. PubMed ID: 20385869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein.
    Shannon-Lowe CD; Emery VC
    Herpesviridae; 2010 Dec; 1(1):4. PubMed ID: 21429239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
    Chou S; Bowlin TL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):382-4. PubMed ID: 21041510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid detection by reverse hybridization of mutations in the UL97 gene of human cytomegalovirus conferring resistance to ganciclovir.
    Zhou L; Harder TC; Ullmann U; Rautenberg P
    J Clin Virol; 1999 Jun; 13(1-2):53-9. PubMed ID: 10405892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
    Chou S; Marousek GI; Senters AE; Davis MG; Biron KK
    J Virol; 2004 Jul; 78(13):7124-30. PubMed ID: 15194788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
    Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
    Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance.
    Göhring K; Mikeler E; Jahn G; Hamprecht K
    J Clin Microbiol; 2006 Dec; 44(12):4541-4. PubMed ID: 17035493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.